Chinese university conducts trials to launch new Covid-19 drug
  Author: Mateen Dalal

Scientists at Peking University in China have successfully conducted tests for a new drug which they claim could help in containing the coronavirus pandemic. Since its outbreak in China, the disease continues to be a m...

Read More >>
Moderna’s Phase 1 vaccine trial produces antibodies against SARS-CoV-2
  Author: Mateen Dalal

Moderna, Inc., an American biotechnology company, recently announced that its coronavirus vaccine candidate has produced protective antibodies among a group of healthy volunteers. E...

Read More >>
Gilead inks non-exclusive licensing pacts with 5 generic drug-makers
  Author: Mateen Dalal

Gilead Sciences, an American biopharmaceutical company, has recently inked non-exclusive licensing pacts with 5 India- and Pakistan-based generic drug-makers. These licensing agreements have been made to increase the s...

Read More >>
South Korea delays school reopening due to new COVID-19 cluster
  Author: Mateen Dalal

South Korea has delayed the process of reopening schools by a week due to the fears of possible 2nd wave of COVID-19 infections. The latest coronavirus cases stem from a new cluster traced to 5 clubs and bars in Itaewon. The number of infe...

Read More >>
Enlivex commences phase II study of Allocetra in COVID-19 patients
  Author: Mateen Dalal

The world has joined forces to develop a vaccine for COVID-19 and companies across the globe are scrambling for the first breakthrough. Since the coronavirus spreads easily and is already weakening the healthcare syste...

Read More >>
Gilead in talks with Indian drug producers to offer patented remdesivir
  Author: Mateen Dalal

Gilead Sciences, an American biopharmaceutical company, has recently engaged in talks with some leading chemical & pharmaceutical companies in countries including India. The discussion has been held on remdesivir, ...

Read More >>
HSA issues stern warning over falsely advertised health products
  Author: Mateen Dalal

Singapore’s health statutory board, the Health Sciences Authority (HSA) has recently deleted over 1,700 listings of products from local websites that were falsely making COVID-19-related claims. These products in...

Read More >>
University Hospital Southampton tests Synairgen’s new COVID-19 drug
  Author: Mateen Dalal

UK scientists have developed a new drug for treating coronavirus patients that will be put to trial in the University Hospital at Southampton. UK-based biotech firm, Synairgen has developed this drug which uses the pro...

Read More >>
Gilead Sciences shows positive results for remdesivir as COVID-19 drug
  Author: Mateen Dalal

Gilead Sciences, the maker of remdesivir, has recently revealed positive results from trials for the drug. The trials were conducted to evaluate the potential of the medication as a treatment for the novel coronavirus....

Read More >>
Victoria set for 100,000 COVID-19 tests prior to ease of restrictions
  Author: Mateen Dalal

Daniel Andrews, the Premier of Victoria, has reportedly stated that 100,000 COVID-19 tests will be conducted in 2 weeks ahead of easing of stage 3 restrictions. Mr. Andrews has adde...

Read More >>
Practitioners doubt the efficacy of hydroxychloroquine for COVID-19
  Author: Mateen Dalal

As the debate on hydroxychloroquine’s effectiveness over COVID-19 intensifies, a significant number of physicians across the globe still presume that patients should consume the drug to treat the symptoms of COVI...

Read More >>
Ramsay Health Care lauds Australia’s plan to resume elective surgeries
  Author: Mateen Dalal

Ramsay Health Care, a leading provider of healthcare services in Australia, Malaysia, Indonesia and the U.K, has reportedly welcomed a plan proposed by Australia to resume elective surgeries, considering it as a decent...

Read More >>
Novartis receives FDA nod for malaria drug trial on COVID-19 patients
  Author: Mateen Dalal

Novartis has received approval from the U.S. Food and Drug Administration for clinical trials to study the efficacy of hydroxychloroquine, which is essentially a drug for malaria, for the treatment of hospitalized pati...

Read More >>
Oxford University to commence human trials on a COVID-19 vaccine
  Author: Nikita Chaurasia

The university’s vaccine programme has hired around 510 people to take part in the first trial. As the deadly coronavirus have paved its way to almost every c...

Read More >>
UK regulator gives green light to Penlon’s ESO2 medical ventilator
  Author: Mateen Dalal

As the COVID-19 pandemic has significantly increased the demand for ventilators, leading manufacturers worldwide have responded quickly by surging production. However, ventilator manufacturers are still waiting to get ...

Read More >>
GSK & Sanofi join forces to discover an effective vaccine for COVID-19
  Author: Nikita Chaurasia

Amidst growing concerns over the coronavirus, numerous medical institutes and pharmaceutical companies are diligently working on developing an effective vaccine to tackle this deadly virus. France’s Sanofi S.A. a...

Read More >>
Mayo Clinic & the University of Minnesota offer antibody testing
  Author: Mateen Dalal

In a bid to curb the spread of coronavirus, several medical institutes and researchers are conducting striding initiatives like community-wide testing and drug development. Recently, the University of Minnesota and May...

Read More >>
Kentucky & Kroger team up to open drive-thru COVID-19 testing centers
  Author: Mateen Dalal

The Governor of Kentucky, Andy Beshear has reportedly stated that the state of Kentucky is teaming up with renowned retail chain company, Kroger, to open free drive-thru coronavirus testing centers throughout the state...

Read More >>
AIVITA declares updates for AV-GMB-1 clinical trial in GBM patients
  Author: Mateen Dalal

AIVITA Biomedical, Inc., a biotech firm developing innovative cell therapies, has recently announced updates to the survival data after the year-end analysis of the ongoing AV-GBM-1 Phase 2 clinical trial in newly diag...

Read More >>
Walgreens will provide drive-thru testing for COVID-19 in 7 US states
  Author: Mateen Dalal

Walgreens, a leading drug store chain in the United States recently announced plans to open 15 drive-thru facilities for coronavirus COVID-19 testing in seven states. With mounting ...

Read More >>
Australian researchers discover anti-parasite drug that kills COVID-19
  Author: Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world ...

Read More >>
Gilead to donate 1.5M doses of remdesivir to treat COVID-19 patients
  Author: Mateen Dalal

Gilead Sciences, Inc., an American biotechnology company, has recently announced its plan to donate 1.5 million doses of the investigational drug, remdesivir. These 1.5 million doses will be used for over 140,000 treat...

Read More >>
Home Depot to reserve masks for frontline healthcare professionals
  Author: Mateen Dalal

As COVID-19 cases continue to soar in America, medical professionals on the front lines are facing a shortage of masks and other protective equipment. To cope up with increasing demand, The Home Depot Inc., one of the ...

Read More >>
Analytics 4 Life reveals new data backing novel method to predict LVEDP
  Author: Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiolo...

Read More >>
1CellBio to provide early access to new targeted cell sequencing
  Author: Mateen Dalal

The U.S.-based biotechnology company, 1CellBio Inc. has recently revealed early access program for its latest droplet-based targeted cell sequencing and selection abilities. Reportedly, this latest approach aligns with...

Read More >>
Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
  Author: Nikita Chaurasia

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showca...

Read More >>
Novartis releases Phase 3 trial data that assesses hyperlipidemia drug
  Author: Mateen Dalal

Novartis, a renowned biopharmaceutical company, has reportedly released the outcomes of a prespecified analysis of pooled information from three Phase 3 trials that evaluate the efficacy and safety of inclisiran, the c...

Read More >>
miDiagnostics secures €14M to commercialize rapid clinical testing
  Author: Mateen Dalal

Leuven-based biotech firm miDiagnostics has recently concluded a €14 million investment round. The funding round was led by leading life science and technology investors, including Dr. Ir. Urbain Vandeurzen and Dr...

Read More >>
ATUM to offer Protein Synthesis Platform to COVID-19 test tool developers
  Author: Mateen Dalal

As the coronavirus pandemic reaches community level, prominent companies have come forward to aid medical researchers in accelerating their drug development process. ATUM, an American biotechnology firm, recently made ...

Read More >>
Researchers in UK develop a new, low-cost test kit for COVID-19
  Author: Nikita Chaurasia

Amidst growing concerns over the coronavirus pandemic, several health researchers have started to innovate new medical apparatus and drugs to help combat this novel virus. Recently, a bunch of researchers from the Univ...

Read More >>
InMed files CTA to start second Phase 1 INM-755 clinical trial
  Author: Nikita Chaurasia

InMed Pharmaceuticals Inc., a leading biopharmaceutical company which develops medications targeting diseases with unmet needs, has reportedly announced the filing of CTA (Clinical Trial Application) in the Netherlands...

Read More >>
Vapotherm reveals business update following COVID-19 pandemic
  Author: Nikita Chaurasia

Vapotherm, Inc., a global medical technology firm developing and manufacturing proprietary Hi-VNI Technology products, has reportedly announced an update on its business in response to the COVID-19 pandemic. ...

Read More >>
Ology Bioservices, DOD offer $14Mn to develop COVID-19 antibody
  Author: Mateen Dalal

In a bid to expedite the COVID-19 drug development process, Ology Bioservices Inc., a privately held American biopharmaceutical firm, along with the Department of Defense (DOD) decided to award a contract worth $14 million, to manufacture and deve...

Read More >>
GeNeuro temporarily suspends MS trial, will focus on COVID-19 efforts
  Author: Mateen Dalal

The pharmaceutical firm will prioritize resources towards COVID-19 pandemic Phase 2 trial in MS patients will commence once the hospitals hav...

Read More >>
Saniona finishes six months double blind Phase 2a trial of Tesomet
  Author: Mateen Dalal

Saniona, a renowned biopharmaceutical firm focusing on rare disorders of the central nervous system, has reportedly announced that the last patient has successfully completed the last visit in the company’s six-m...

Read More >>
CERo confirms research partnership and $40 million funding round
  Author: Mateen Dalal

CERo Therapeutics, Inc., the privately-owned biopharma firm, recently announced that it will be collaborating for research with Lyell Immunopharma, Inc. for the development of next-gen cell-based immunotherapy solution...

Read More >>
U.S. cardiac care startup Heartbeat Health secures US$8.2 million
  Author: Mateen Dalal

The series A funding round was led by Optum Ventures and .406 ventures The company aims at expanding the delivery of advanced virtual cardiovascula...

Read More >>
QED Therapeutics doses first patients in infigratinib clinical trials
  Author: Mateen Dalal

The trial monitors infigratinib in the post-surgery treatment of invasive urothelial carcinoma   Volunteers with a high risk of cancer ...

Read More >>
Bio-Rad rolls out SARS CoV-2 standards for Coronavirus Testing
  Author: Nikita Chaurasia

The SARS CoV-2 standard has human genomic DNA and synthetic COVID-19 RNA transcripts.   SARS CoV-2 standard assists laboratories to kee...

Read More >>
UnitedHealthcare rolls out new eye care benefit program for women
  Author: Nikita Chaurasia

UnitedHealth Group Inc., an American healthcare company offering a full spectrum of health benefit programs for employers, individuals, and medicaid beneficiaries, has reportedly launched a new benefit program to suppo...

Read More >>
CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
  Author: Mateen Dalal

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to off...

Read More >>
Alkahest doses first patient in Phase 2 trial for Parkinson’s therapy
  Author: Mateen Dalal

Alkahest will initiate Phase 2 trial for AKST4290, an inhibitor to treat Parkinson’s disease The firm has been partly funded by The Michael J...

Read More >>
Moleculin announces US Phase 1 AML trial completion for Annamycin
  Author: Mateen Dalal

Moleculin Biotech, Inc., a preclinical pharmaceutical company and developer of anti-cancer drug candidates, has recently announced the completion of its US Phase 1 trial. The open label, single arm clinical trial met i...

Read More >>
AntiCancer to test its methioninase as a new treatment for coronavirus
  Author: Mateen Dalal

The threat of coronavirus needs to be addressed as early as possible, particularly since there are no particular treatments or vaccines currently available for patients suffering from coronavirus globally. As the count...

Read More >>
EyeTech unveils advanced eye tracking tablet platform, EyeOn™
  Author: Nikita Chaurasia

The tablet would offer superior performance as well as premium design for AAC users. EyeTech Digital Systems, a leading innovator in Health AI, has recently launche...

Read More >>
Terrace Global enters into genetics supply agreement with Apollo Green
  Author: Mateen Dalal

Under the exclusive genetics supply agreement, the parties would possibly acquire and import high-THC genetics for Terrace’s medical cannabis operations in the state of Portugal. The company is all s...

Read More >>
ASP secures the U.S. FDA approval for STERRAD VELOCITY® BI/PCD
  Author: Nikita Chaurasia

Advanced Sterilization Products (ASP) has secured 510(k) clearance from the U.S. FDA. The regulatory body has approved for a 15-min time to result on the STERRAD VELOCITY® Biological Indicator (BI)/P...

Read More >>
Omnicell to present its newest innovations in medication management
  Author: Mateen Dalal

Omnicell, Inc., a U.S. based company that offers adherence tools for healthcare systems and pharmacies along with medication management solutions, has recently revealed that it would be presenting its medication management portfolio’s latest...

Read More >>
MyndVR-Vi unite to deliver VR care services at Palo Alto CCRCs
  Author: Mateen Dalal

MyndVR, a leading health and wellness company providing virtual reality solutions to senior living communities, has recently announced its partnership with Vi. Vi is a leading continuing care retirement community (CCRC...

Read More >>
Quest Diagnostics announces acquisition of Blueprint Genetics
  Author: Mateen Dalal

Quest Diagnostics announced the acquisition of genetic testing firm, Blueprint Genetics to extend access to actionable insights in genetic and rare diseases. The acquisition is aimed at enhancing patient care and boost...

Read More >>
The U.S. FDA authorizes Tepezza to treat thyroid eye disease in adults
  Author: Mateen Dalal

The U.S. FDA (Food and Drug Administration), a federal agency of the U.S. Department of Health and Human Services, has reportedly approved teprotumumab-trbw (Tepezza) to treat adults suffering from thyroid eye disease....

Read More >>
Dermtech signs a commercial & medicare advantage coverage agreement
  Author: Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmente...

Read More >>
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
  Author: Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycofo...

Read More >>
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
  Author: Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-0...

Read More >>
Adverum reviews recent business progress and unveils its 2020 outlook
  Author: Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. ...

Read More >>
Adverum presents data from OPTIC Phase 1 study of ADVM-022
  Author: Mateen Dalal

Adverum Biotechnologies, Inc., a U.S. based biotechnology company that develops innovative therapies for ocular and rare diseases, has announced its first patient data from the OPTIC phase 1 clinical study of ADVM-022,...

Read More >>
Immunic exercises exclusive IMU-856 global license option from Daiichi
  Author: Mateen Dalal

Immunic, a renowned biopharmaceutical company focused on treating autoimmune and chronic inflammatory diseases, reportedly announced that its subsidiary, Immunic AG, has implemented its exclusive global license option ...

Read More >>
Medtronic buys spinal cord stimulation therapy developer Stimgenics
  Author: Mateen Dalal

DTM waveform will help improve the outcome for patients with chronic pain   The transaction will remain neutral to earnings per share f...

Read More >>
BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy
  Author: Mateen Dalal

The report will contain data of CAR-T product candidate called BNT211, an autologous CAR-T cell therapy BioNTech SE, a biotechnology firm based in Germany, recently...

Read More >>
EMA approves marketing authorization application for Lumoxiti®
  Author: Mateen Dalal

Innate Pharma SA, a commercial-stage oncology-focused biotech firm, has successfully attain Marketing Authorization Application (MMA) approval for Lumoxiti from the European Medicines Agency (EMA). For the record, Lumo...

Read More >>
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
  Author: Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the ...

Read More >>
Starpharma initiates Phase 1 study for AZD0466 using DEP® platform
  Author: Mateen Dalal

Starpharma, a world leader in dendrimer product development, reportedly announced that AstraZeneca, a renowned British-Swedish biopharmaceutical company, has initiated a phase 1 clinical study of AZD0466. The first pat...

Read More >>
Spring Bank refrains from dosing patients in Inarigivir clinical trials
  Author: Mateen Dalal

Clinical-stage biopharmaceutical company, Spring Bank Pharmaceuticals, Inc. has reportedly stopped patient dosing and enrollment in its Phase 2b CATALYST studies that aim at evaluating the use of inarigivir soproxil 40...

Read More >>
Iterum declares completion of enrollment in sulopenem clinical trial
  Author: Mateen Dalal

The clinical trial was aimed at the treatment of uncomplicated urinary tract infections. The enrollment is expected to garner topline results in q...

Read More >>
Lineage Cell Therapeutics unveils plans to ink three new license deals
  Author: Mateen Dalal

Lineage Cell Therapeutics, a California based clinical stage biotechnology company, that develops novel cellular therapies for medical needs that are not fulfilled, has reportedly announced its plans to enter into lice...

Read More >>
ViiV gets CRL from FDA for rilpivirine and cabotegravir to treat HIV
  Author: Mateen Dalal

HIV AIDS cases have been prevailing and increasingly growing across the world. Currently, about 37.9 million people are suffering from HIV globally. Several global pharmaceutical firms are increasingly working and inve...

Read More >>
Seattle Genetics & Astellas bag accelerated approval for PADCEV™
  Author: Mateen Dalal

Seattle Genetics, Inc., a biotechnology company based in U.S., and Astellas Pharma Inc. have recently revealed that the U.S. Food and Drug Administration (FDA) has given PADCEV™ an accelerated approval for treati...

Read More >>
Cigna sells non-medical insurance unit to New York Life Insurance
  Author: Mateen Dalal

The deal is anticipated to close in the third quarter of 2020, subject to relevant regulatory approvals and other customary closing terms. Cigna has reportedly anno...

Read More >>
FDA approves TransThera’s IND for TT-00920 to treat heart failure
  Author: Mateen Dalal

TransThera will initiate a Phase 1 clinical trial for TT-00920 in early 2020   TT-00920 is believed to be a new transformative treatmen...

Read More >>
Union Medical uses Photon Control’s optical sensors in medical device
  Author: Mateen Dalal

The optical sensors are designed to integrate into Union Medical’s Neo Thermos   Neo Thermos is utilized to treat tumors without ...

Read More >>
Myriad Genetics validates polygenic risk score for breast cancer
  Author: Mateen Dalal

Myriad Genetics, Inc., a company focused on precision medicine and molecular diagnostics, has reportedly presented the result of a new validation study of its polygenic risk score (PRS) for breast cancer at the 2019 Sa...

Read More >>
Cergentis rolls out TLA technology for cancer gene mutation sequencing
  Author: Mateen Dalal

  The genomics company announced the launch of Targeted Locus Amplification (TLA) technology for complete cancer gene mutation sequencing. ...

Read More >>
ProQR doses first patient in Phase 1/2 Aurora trial targeting adRP
  Author: Mateen Dalal

ProQR Therapeutics NV, a renowned Dutch biopharmaceutical company dedicated on finding treatments for rare genetic diseases, has reportedly announced the dosage of first patient in Phase 1/2 Aurora study of QR-1123....

Read More >>
Merck & Co. to acquire ArQule to advance leadership in oncology
  Author: Mateen Dalal

Merck, a renowned American pharmaceutical company also known as MSD outside Canada and the United States, reportedly announced the acquisition of ArQule, a US-based biopharmaceutical firm focused on finding novel thera...

Read More >>
IMV announces updated data for Phase 2 DPX-Survivac trial in r/r DLBCL
  Author: Mateen Dalal

The updated results were presented in poster session at the ASH annual meeting   The study shows strong data for DPX-Survivac in combin...

Read More >>
Kura Oncology announces regulatory & clinical updates for Tipifarnib
  Author: Mateen Dalal

Kura Oncology, Inc., a biopharmaceutical firm based in the U.S., has recently revealed regulatory and clinical updates of its foremost drug candidate, Tipifarnib, designed to target AITL (angioimmunoblastic T-cell lymp...

Read More >>
Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
  Author: Mateen Dalal

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug...

Read More >>
Prescient expands PTX-200 trial after it eradicates cancer completely
  Author: Mateen Dalal

Prescient Therapeutics, a renowned small molecule drug development firm aimed at developing new cancer therapies, reportedly announced that it is extending its Phase 1b trial in patients with AML (acute myeloid leukemi...

Read More >>
Equillium to present data supporting CD6-ALCAM at ASH annual meet
  Author: Nikita Chaurasia

Equillium Inc., a clinical-stage biotechnology company, has reportedly announced that it will be presenting positive data related to the role CD6-ALCAM pathway as a relevant target for patients who are suffering from a...

Read More >>
HeartVista to present AI-based Cardiac MRI Solution at RSNA annual meet
  Author: Mateen Dalal

As an innovative technology, artificial intelligence can effectively be used to tackle the challenges faced by today’s healthcare industry. Hospitals are keenly looking for ways to serve patients, both in terms o...

Read More >>
Asuragen & Wave Life Sciences unite for development of HD diagnostics
  Author: Nikita Chaurasia

It has been reported that various industry giants across the medical fraternity have been involved in the mergers and collaborations to develop and commercialize the treatments for distinguished disorders and diseases....

Read More >>
The Medicines Company’s worth declared at $9.7bn post Novartis’ buyout
  Author: Nikita Chaurasia

Novartis has reportedly planned the purchase with a target of adding inclisiran, a potential cholesterol lowering drug of The Medicines Company to its existing cardiovascular portfolio ...

Read More >>
Eidos & biotechnology firm BridgeBio present data from phase 2 OLE
  Author: Nikita Chaurasia

  Lower rates of cardiovascular hospitalizations and mortality were witnessed. Echocardiographic paramete...

Read More >>
FDA warns Dollar Tree regarding the sale of imported adulterated drugs
  Author: Mateen Dalal

FDA’s new warning letter is asking Dollar Tree to ensure the company does not import adulterated medicines   Manufacturers mentio...

Read More >>
Cellectis reveals POC for smart T-cells that recognize tumors
  Author: Mateen Dalal

Cellectis, a French biopharmaceutical company that aims to innovate immunotherapies based on gene-edited allogeneic CAR T-cells, recently revealed a report issued in Nature Communications that explains a proo...

Read More >>
Arranta Bio acquires Captozyme to accelerate microbiome development
  Author: Mateen Dalal

Arranta has established a Center of Excellence for microbiome development   The acquisition will help quicken the delivery of LBPs for ...

Read More >>
CytoDyn obtains IRB approval for leronlimab for patients with TNBC
  Author: Mateen Dalal

Reports confirm that CytoDyn Inc., a late-stage biotechnology company has announced that it has recently received approval from the Institutional Review Board for leronlimab, to be directed to triple-n...

Read More >>
FDA declines approval of Lipocine’s oral drug Tlando for third time
  Author: Mateen Dalal

FDA declines approval of Lipocine’s oral drug Tlando for third time Reportedly, the oral drug Tlando was first declined  approva...

Read More >>
GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®
  Author: Mateen Dalal

GW Pharmaceuticals plc has reportedly announced that two of its medicines, Sativex (nabiximols) and EPIDYOLEX (cannabidiol) oral solution, have been advised by National Institute for Health and Care Excellence (NICE) of the U.K. to get routine com...

Read More >>
Chembio announces WHO Prequalification approval for HIV Self-Test
  Author: Nikita Chaurasia

The test senses antibodies to HIV 1 and HIV 2, demonstrated specificity of 100% and sensitivity of 99.4%, when comparing amateur HIV self-test users to skilled professionals. ...

Read More >>